Luteolin (Synonyms: 木犀草素; Luteoline; Luteolol; Digitoflavone)

目录号: HY-N0162 纯度: 99.51%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Luteolin (Luteoline), 一种黄酮类化合物，也是一种有效的 Nrf2 抑制剂。Luteolin 具有抗炎和抗癌特性，可在人类多种癌细胞系 (包括非小肺癌细胞) 中诱导细胞凋亡和细胞周期停滞，并抑制细胞转移和血管生成。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Luteolin Chemical Structure

CAS No. : 491-70-3

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥550	In-stock
5 mg	￥312	In-stock
10 mg	￥473	In-stock
25 mg	￥555	In-stock
50 mg	￥650	In-stock
100 mg	￥920	In-stock
500 mg	￥2550	In-stock
1 g		询价
5 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Luteolin:

Luteolin monohydrate In-stock
Luteolin (Standard) In-stock

MCE 顾客使用本产品发表的 40 篇科研文献

: Luteolin purchased from MCE. Usage Cited in: Front Pharmacol. 2018 Jun 13;9:620. [Abstract]; Effects of Luteolin on the level of CTSD and p-CDK2 in HK-2 cells. The western blotting results of CTSD and p-CDK2 in the NaOx-stimulated HK-2 cells treated by Luteolin.

Luteolin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells^[1]^[2]^[3].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	10.23 μg/mL Compound: Luteolin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21106454]
A549	IC₅₀	12.9 mg/mL Compound: 17	Cytotoxicity against human A549 cells after 3 days by SRB assay Cytotoxicity against human A549 cells after 3 days by SRB assay	[PMID: 15568778]
B16-4A5	IC₅₀	> 100 μM Compound: 15	Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay	[PMID: 20189399]
B16-4A5	IC₅₀	14 μM Compound: 2	Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs by microplate reader analysis Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs by microplate reader analysis	[PMID: 25987378]
B16-4A5	IC₅₀	14 μM Compound: 15	Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs	[PMID: 20189399]
BXPC-3	GI₅₀	> 10 μg/mL Compound: 4	Cytotoxicity against human BxPC3 cells after 48 hrs by SRB assay Cytotoxicity against human BxPC3 cells after 48 hrs by SRB assay	[PMID: 12608861]
C8166	CC₅₀	17.9 μg/mL Compound: 3	Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24794743]
C8166	EC₅₀	2.48 μg/mL Compound: 3	Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis	[PMID: 24794743]
Ca9-22	IC₅₀	8.55 μg/mL Compound: Luteolin	Cytotoxicity against human Ca9-22 cells by MTT assay Cytotoxicity against human Ca9-22 cells by MTT assay	[PMID: 21106454]
CCRF-CEM	IC₅₀	> 10 μg/mL Compound: 9	Cytotoxicity against human CEM cells after 3 days by MTT assay Cytotoxicity against human CEM cells after 3 days by MTT assay	[PMID: 11421746]
DU-145	GI₅₀	4.4 μg/mL Compound: 4	Cytotoxicity against human DU145 cells after 48 hrs by SRB assay Cytotoxicity against human DU145 cells after 48 hrs by SRB assay	[PMID: 12608861]
Erythrocyte	EC₅₀	107.28 μg/mL Compound: Luteolin	Hemolysis of human erythrocytes after 30 mins by spectrophotometry Hemolysis of human erythrocytes after 30 mins by spectrophotometry	[PMID: 23811092]
H9	EC₅₀	10 μM Compound: 3	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay	[PMID: 8158164]
H9	IC₅₀	16 μM Compound: 3	Cytotoxicity against human H9 cells after 3 days Cytotoxicity against human H9 cells after 3 days	[PMID: 8158164]
H9c2	EC₅₀	5.53 μM Compound: 16	Cytoprotective activity against doxorubicin-induced cytotoxicity in rat H9c2 cells assessed as cell viability after 24 hrs by MTT assay Cytoprotective activity against doxorubicin-induced cytotoxicity in rat H9c2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 20932762]
HCT-116	EC₅₀	26.7 μM Compound: Luteolin	Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26529431]
HEK293	IC₅₀	> 10 μM Compound: 25	Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay	[PMID: 30943030]
HEK293	IC₅₀	0.85 μM Compound: 7e	Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay	[PMID: 20731357]
HEK293	EC₅₀	2.3 μM Compound: 16	Agonist activity at mouse PPARgamma expressed in HEK293 cells co-expressing with Gal4 reporter vector after 24 hrs by dual-luciferase reporter assay Agonist activity at mouse PPARgamma expressed in HEK293 cells co-expressing with Gal4 reporter vector after 24 hrs by dual-luciferase reporter assay	[PMID: 24955889]
Hep 3B2	IC₅₀	8.03 μg/mL Compound: Luteolin	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 21106454]
HepG2	IC₅₀	34.7 μM Compound: Luteolin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26896708]
HepG2	IC₅₀	47.3 μM Compound: 16	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
HepG2	IC₅₀	7.36 μg/mL Compound: Luteolin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 21106454]
HepG2	IC₅₀	71.2 μM Compound: 31	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 21726077]
HepG2	IC₅₀	80.8 μM Compound: 8	Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24974349]
HL-60	IC₅₀	> 10 μg/mL Compound: 9	Cytotoxicity against human HL60 cells after 3 days by MTT assay Cytotoxicity against human HL60 cells after 3 days by MTT assay	[PMID: 11421746]
HL-60	IC₅₀	> 100 μM Compound: Luteolin	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27353532]
HT-29	IC₅₀	18.6 μM Compound: Luteolin	Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins	[PMID: 24900447]
HT-29	IC₅₀	45 μM Compound: 40	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTS assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTS assay	[PMID: 31324564]
HT-29	EC₅₀	7.24 μM Compound: Luteolin	Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay	[PMID: 24900447]
Huh-7	CC₅₀	> 50 μM Compound: 22	Cytotoxicity against human Huh7.5.1 cells by MTT assay Cytotoxicity against human Huh7.5.1 cells by MTT assay	[PMID: 22445328]
Huh-7	EC₅₀	4.7 μM Compound: 22	Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay	[PMID: 22445328]
Huh-7	EC₅₀	6.6 μM Compound: 22	Antiviral activity against HCV genotype 2a J399LM in Human Huh7.5.1 replicon cells assessed as suppression of viral replication after 72 hrs by luciferase reporter gene assay Antiviral activity against HCV genotype 2a J399LM in Human Huh7.5.1 replicon cells assessed as suppression of viral replication after 72 hrs by luciferase reporter gene assay	[PMID: 22445328]
Jurkat	IC₅₀	1.3 μM Compound: Luteolin	Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method	[PMID: 30776692]
Jurkat	IC₅₀	1.5 μM Compound: Luteolin	Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method	[PMID: 30776692]
K562	IC₅₀	14.65 μM Compound: 2, luteolin	Growth inhibition of K562 cells by XTT assay after 5 days Growth inhibition of K562 cells by XTT assay after 5 days	[PMID: 17411092]
KB	IC₅₀	45.3 μM Compound: 16	Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
KM-20L2	GI₅₀	> 10 μg/mL Compound: 4	Cytotoxicity against human KM20L2 cells after 48 hrs by SRB assay Cytotoxicity against human KM20L2 cells after 48 hrs by SRB assay	[PMID: 12608861]
L02	IC₅₀	> 100 μM Compound: Luteolin	Cytotoxicity against human LO2 cells after 48 hrs by MTT assay Cytotoxicity against human LO2 cells after 48 hrs by MTT assay	[PMID: 26896708]
L6	IC₅₀	21.4 μg/mL Compound: 21	Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by photometric method Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by photometric method	10.1039/C5MD00481K
L6	IC₅₀	9.4 μg/mL Compound: 21	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining based fluorescence analysis Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining based fluorescence analysis	10.1039/C5MD00481K
L929	EC₅₀	> 250 μM Compound: luteolin	Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining	[PMID: 9287415]
L929	EC₅₀	> 250 μM Compound: luteolin	Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay	[PMID: 9287415]
Lu1	IC₅₀	40.8 μM Compound: 16	Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
MCF7	IC₅₀	14.3 mg/mL Compound: 17	Cytotoxicity against human MCF7 cells after 3 days by SRB assay Cytotoxicity against human MCF7 cells after 3 days by SRB assay	[PMID: 15568778]
MCF7	IC₅₀	44.4 μM Compound: 16	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
MCF7	IC₅₀	5 μM Compound: Luteolin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay	[PMID: 33257172]
MCF7	GI₅₀	9.4 μg/mL Compound: 4	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 12608861]
MCF7	IC₅₀	9.5 μg/mL Compound: Luteolin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 21106454]
MDA-MB-231	IC₅₀	7.29 μM Compound: Luteolin	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34971873]
MDA-MB-231	IC₅₀	9.65 μg/mL Compound: Luteolin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 21106454]
MDCK	CC₅₀	12.44 μM Compound: 2	Cytotoxicity against MDCK cells by MTT assay Cytotoxicity against MDCK cells by MTT assay	[PMID: 18640042]
MDCK	CC₅₀	164.9 μM Compound: 2	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 19729316]
MOLM-13	IC₅₀	4.5 μM Compound: 25	Cytotoxicity against human MOLM-13 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MOLM-13 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026809]
Monocyte	IC₅₀	1.5 μM Compound: luteolin	Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs	[PMID: 8882428]
MV4-11	GI₅₀	1.76 μM Compound: 3	Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay	[PMID: 23411073]
MV4-11	IC₅₀	3.1 μM Compound: 25	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026809]
NCI-H460	GI₅₀	3.8 μg/mL Compound: 4	Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 12608861]
NCI-H460	IC₅₀	8.9 μM Compound: 11	Inhibition of ABCG2 expressed in human NCI-H460 cells assessed as inhibition of PhA accumulation after 2 to 20 hrs relative to fumitremorgin C Inhibition of ABCG2 expressed in human NCI-H460 cells assessed as inhibition of PhA accumulation after 2 to 20 hrs relative to fumitremorgin C	[PMID: 21275386]
Neutrophil	IC₅₀	0.9 μM Compound: 4e	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	1.7 μM Compound: 6	Inhibition of PMA-induced oxidative burst in human neutrophils by amplex red assay Inhibition of PMA-induced oxidative burst in human neutrophils by amplex red assay	[PMID: 25151578]
Neutrophil	IC₅₀	2.2 μM Compound: 6	Inhibition of PMA-induced oxidative burst in human neutrophils by APF assay Inhibition of PMA-induced oxidative burst in human neutrophils by APF assay	[PMID: 25151578]
Neutrophil	IC₅₀	4 μM Compound: 4e	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	5.2 μM Compound: 6	Inhibition of PMA-induced oxidative burst in human neutrophils by chemiluminescence assay Inhibition of PMA-induced oxidative burst in human neutrophils by chemiluminescence assay	[PMID: 25151578]
Neutrophil	IC₅₀	9.3 μM Compound: 4e	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	9.5 μM Compound: 4e	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
P388	GI₅₀	> 10 μg/mL Compound: 4	Cytotoxicity against mouse P388 cells after 48 hrs by SRB assay Cytotoxicity against mouse P388 cells after 48 hrs by SRB assay	[PMID: 12608861]
Peritoneal macrophage	IC₅₀	20 μM Compound: kp17	Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method	[PMID: 27955927]
Peritoneal macrophage cell	IC₅₀	77.7 μM Compound: luteolin	Cytotoxicity against mouse Peritoneal macrophages cells after 72 hrs by MTS assay Cytotoxicity against mouse Peritoneal macrophages cells after 72 hrs by MTS assay	[PMID: 22989363]
Platelet	IC₅₀	> 50 μg/mL Compound: Luteolin	Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry	[PMID: 21106454]
Platelet	IC₅₀	2.56 μg/mL Compound: Luteolin	Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry	[PMID: 21106454]
Platelet	IC₅₀	43.5 μM Compound: 6	Inhibition of arachidonic acid-induced platelet aggregation in rabbit plasma preincubated 3 mins before addition of thrombin by turbidimetric method Inhibition of arachidonic acid-induced platelet aggregation in rabbit plasma preincubated 3 mins before addition of thrombin by turbidimetric method	[PMID: 9287421]
RAW264.7	IC₅₀	> 40 μM Compound: Lut.	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32208222]
RAW264.7	IC₅₀	> 50 μM Compound: Luteolin	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability by MTT assay	[PMID: 29655613]
RAW264.7	IC₅₀	0.21 μM Compound: 8	Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells pre-incubated for 2 hrs before LPS stimulation for 24 hrs by Griess assay method Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells pre-incubated for 2 hrs before LPS stimulation for 24 hrs by Griess assay method	[PMID: 25176187]
RAW264.7	IC₅₀	10.4 μM Compound: Luteolin	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 24 hrs by Griess reagent Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 24 hrs by Griess reagent	[PMID: 20363145]
RAW264.7	IC₅₀	14.4 μM Compound: Luteolin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 29655613]
RAW264.7	IC₅₀	18.95 μM Compound: Luteolin	Cytotoxicity against mouse RAW264.7 cells by MTT assay Cytotoxicity against mouse RAW264.7 cells by MTT assay	[PMID: 28408221]
RAW264.7	IC₅₀	2.87 μM Compound: Luteolin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated PGE2 production by ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated PGE2 production by ELISA	[PMID: 28408221]
RAW264.7	IC₅₀	43.2 μM Compound: luteolin	Cytotoxicity against mouse RAW264.7 cells after 72 hrs by MTS assay Cytotoxicity against mouse RAW264.7 cells after 72 hrs by MTS assay	[PMID: 22989363]
RAW264.7	IC₅₀	5.06 μM Compound: Luteolin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production by ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production by ELISA	[PMID: 28408221]
RAW264.7	IC₅₀	5.6 μM Compound: Luteolin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess assay	[PMID: 28960981]
RAW264.7	IC₅₀	5.8 μM Compound: Luteolin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs by by Griess assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs by by Griess assay	[PMID: 31419126]
RAW264.7	IC₅₀	7.2 μM Compound: 12	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by Griess reaction based method Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by Griess reaction based method	[PMID: 25637363]
RAW264.7	IC₅₀	7.5 μM Compound: 6	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs by Griess reagent method Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs by Griess reagent method	[PMID: 19778086]
RAW264.7	IC₅₀	8.1 μM Compound: 13	Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 31747281]
RAW264.7	IC₅₀	9.2 μM Compound: Lut.	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay	[PMID: 32208222]
RBL-2H3	IC₅₀	58.2 μM Compound: 6	Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge	[PMID: 14510616]
RBL-2H3	IC₅₀	82 μM Compound: Luteolin	Inhibition of rat RBL2H3 cell degranulation assessed as inhibition of beta-hexosamidase release after 10 mins by microplate reader assay Inhibition of rat RBL2H3 cell degranulation assessed as inhibition of beta-hexosamidase release after 10 mins by microplate reader assay	[PMID: 12398545]
RS4-11	GI₅₀	7.25 μM Compound: 3	Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay	[PMID: 23411073]
SF-268	GI₅₀	9 μg/mL Compound: 4	Cytotoxicity against human SF268 cells after 48 hrs by SRB assay Cytotoxicity against human SF268 cells after 48 hrs by SRB assay	[PMID: 12608861]
SW1573	IC₅₀	> 10 μg/mL Compound: 9	Cytotoxicity against human SW1573 cells after 3 days by MTT assay Cytotoxicity against human SW1573 cells after 3 days by MTT assay	[PMID: 11421746]
THP-1	IC₅₀	70 μM Compound: Luteolin	Cytotoxicity against human THP1 cells after 24 hrs by MTS assay Cytotoxicity against human THP1 cells after 24 hrs by MTS assay	[PMID: 19879672]
U2OS	EC₅₀	3.2 μM Compound: Luteolin	Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay	[PMID: 24900447]
U-937	IC₅₀	20 μM Compound: 29, luteolin	Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	28 μM Compound: 29, luteolin	Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	36 μM Compound: 29, luteolin	Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay	[PMID: 17158054]
Vero	CC₅₀	0.155 mM Compound: 13	Cytotoxicity against african green monkey Vero cells incubated for 3 days Cytotoxicity against african green monkey Vero cells incubated for 3 days	[PMID: 32539378]
Vero C1008	CC₅₀	0.155 μM Compound: 40	Cytotoxicity against African green monkey Vero E6 cells by MTT assay Cytotoxicity against African green monkey Vero E6 cells by MTT assay	[PMID: 33486200]

体外研究
(In Vitro)

Luteolin (0-160 μM; 24 hours; NCI-H460 cells) treatment inhibits the viability of NCI-H460 cells in a concentration-dependent manner^[1].
Luteolin (20-80 μM; 24 hours; NCI-H460 cells) treatment causes an accumulation of cells in the S phase^[1].
Luteolin (320-580 μM; 48 hours; NCI-H460 cells) treatment induces apoptosis^[1].
Luteolin (20-80 μM; 24 hours; NCI-H460 cells) treatment increases the protein expression levels of apoptotic regulatory proteins, including the Bax/Bcl-2 ratio, in a concentration-dependent manner, however, only 80 μM Luteolin inhibits the expression of Bad. Luteolin also decreases the expression of Sirt1 in the NCI-H460 cell line in a concentration-dependent manner^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	NCI-H460 cells
Concentration:	0 µM, 20 µM, 40 µM, 80 µM and 160 µM
Incubation Time:	24 hours
Result:	Inhibited the viability of NCI-H460 cells in a concentration-dependent manner.

Cell Cycle Analysis^[1]

Cell Line:	NCI-H460 cells
Concentration:	20 µM, 40 µM, 80 µM
Incubation Time:	24 hours
Result:	Induced cell cycle arrest in the S phase.

Apoptosis Analysis^[1]

Cell Line:	NCI-H460 cells
Concentration:	320 µM, 440 µM, 580 µM
Incubation Time:	48 hours
Result:	Apoptotic fraction was markedly increased.

Western Blot Analysis^[1]

Cell Line:	NCI-H460 cells
Concentration:	20 µM, 40 µM, 80 µM
Incubation Time:	24 hours
Result:	Increased the protein expression levels of apoptotic regulatory proteins and decreased the expression of Sirt1 in the NCI-H460 cell line in a concentration-dependent manner.

体内研究
(In Vivo)

Luteolin (10-100?mg/kg; oral gavage; daily; for 12 weeks; adult male Wistar rats) has an antioxidant effect and can also protect against non-alcoholic steatohepatitis through targeting the pro-inflammatory IL-1 and Il-18 pathways in rats with a high carbohydrate/high fat diet^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male Wistar rats (200-220 g)^[2]
Dosage:	10 mg/kg, 25 mg/kg, 50 mg/kg or 100 mg/kg
Administration:	Oral gavage; daily; for 12 weeks
Result:	Significantly reduced ALT and AST activity and reduced levels of bilirubin, hyaluronic acid and malondialdehyde. Shows an antioxidant activity such as a significant increase in reduced glutathione. IFN-γ, TNF-α, IL-1α and IL-18 levels decreased significantly.

Clinical Trial

分子量

286.24

Formula

C₁₅H₁₀O₆

CAS 号

491-70-3

性状

固体

颜色

Light yellow to yellow

中文名称

木犀草素；檞片素；木樨草素

结构分类

初始来源

微生物

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 100 mg/mL (349.36 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.4936 mL	17.4679 mL	34.9357 mL
5 mM	0.6987 mL	3.4936 mL	6.9871 mL
10 mM	0.3494 mL	1.7468 mL	3.4936 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.27 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： 50% PEG300 50% Saline
Solubility: 20 mg/mL (69.87 mM); 澄清溶液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.51%

选择批次：

Data Sheet (640 KB) SDS (393 KB)

COA (286 KB) LCMS (93 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Ma L, et al. Luteolin exerts an anticancer effect on NCI-H460 human non-small cell lung cancer cells through the induction of Sirt1-mediated apoptosis. Mol Med Rep. 2015 Sep;12(3):4196-4202. [Content Brief]

[2]. Abu-Elsaad N, et al. Protection against nonalcoholic steatohepatitis through targeting IL-18 and IL-1alpha by luteolin. Pharmacol Rep. 2019 Aug;71(4):688-694. [Content Brief]

[3]. Xiuwen Tang, et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med. 2011 Jun 1;50(11):1599-609. [Content Brief]

Luteolin 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.4936 mL	17.4679 mL	34.9357 mL	87.3393 mL
	5 mM	0.6987 mL	3.4936 mL	6.9871 mL	17.4679 mL
	10 mM	0.3494 mL	1.7468 mL	3.4936 mL	8.7339 mL
	15 mM	0.2329 mL	1.1645 mL	2.3290 mL	5.8226 mL
	20 mM	0.1747 mL	0.8734 mL	1.7468 mL	4.3670 mL
	25 mM	0.1397 mL	0.6987 mL	1.3974 mL	3.4936 mL
	30 mM	0.1165 mL	0.5823 mL	1.1645 mL	2.9113 mL
	40 mM	0.0873 mL	0.4367 mL	0.8734 mL	2.1835 mL
	50 mM	0.0699 mL	0.3494 mL	0.6987 mL	1.7468 mL
	60 mM	0.0582 mL	0.2911 mL	0.5823 mL	1.4557 mL
	80 mM	0.0437 mL	0.2183 mL	0.4367 mL	1.0917 mL
	100 mM	0.0349 mL	0.1747 mL	0.3494 mL	0.8734 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Luteolin491-70-3Luteoline Luteolol Digitoflavone木犀草素檞片素木樨草素Keap1-Nrf2ApoptosisAutophagyEndogenous MetaboliteInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Luteolin (Synonyms: 木犀草素; Luteoline; Luteolol; Digitoflavone)

Customer Review

Other Forms of Luteolin:

MCE 顾客使用本产品发表的 40 篇科研文献

Luteolin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Luteolin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Luteolin (Synonyms: 木犀草素; Luteoline; Luteolol; Digitoflavone)

Customer Review

Other Forms of Luteolin:

Luteolin 相关抗体

MCE 顾客使用本产品发表的 40 篇科研文献

Luteolin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

Luteolin 相关抗体:

摩尔计算器

稀释计算器

Luteolin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z